Raising capital for ventures in the psychedelics space presents unique challenges and opportunities, given the evolving legal landscape and the growing interest in psychedelic therapy’s potential. Startups and established companies alike must navigate a complex matrix of regulatory, financial, and strategic considerations to secure funding. This process involves pre-clinical and clinical validation of the therapeutic safety and efficacy of psychedelic molecules or compounds, known as Phase I, II, and III of clinical trials, which can take years to complete and tens of millions of dollars to fund.
At Asebey Life Science Law we work hand-in-hand with corporate and securities law firms* as subject matter experts in order to provide strategic advisory services on developing business plans and slide decks, drafting Term Sheets, structuring investments, negotiating with potential investors, and ensuring regulatory compliance.
We help clients articulate their value proposition, navigate due diligence processes, and execute financial transactions that align with their business goals and regulatory requirements. Our expertise positions our clients to secure the capital they need to innovate and grow in the psychedelics space, paving the way for new treatments and therapies.
*We are not securities attorneys, but co-counsel with corporate and securities firms on capital raises